Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Mizumoto N, Kumamoto T, Robson SC, Sévigny J, Matsue H, Enjyoji K, Takashima A.

Nat Med. 2002 Apr;8(4):358-65.

PMID:
11927941
2.

Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K.

Semin Thromb Hemost. 2005 Apr;31(2):217-33. Review.

PMID:
15852225
3.

Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Thromb Haemost. 2003 Dec;1(12):2497-509. Review. Erratum in: J Thromb Haemost. 2004 Apr;2(4):682.

4.

Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.

Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R.

Semin Thromb Hemost. 2005 Apr;31(2):234-46. Review.

PMID:
15852226
5.

Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Pharmacol Exp Ther. 2003 Apr;305(1):9-16. Review.

6.

Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets.

Atkinson B, Dwyer K, Enjyoji K, Robson SC.

Blood Cells Mol Dis. 2006 Mar-Apr;36(2):217-22. Epub 2006 Feb 13. Review.

PMID:
16476557
7.

Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition.

Gendron FP, Benrezzak O, Krugh BW, Kong Q, Weisman GA, Beaudoin AR.

Curr Drug Targets. 2002 Jun;3(3):229-45. Review.

PMID:
12041737
8.

NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.

Schetinger MR, Morsch VM, Bonan CD, Wyse AT.

Biofactors. 2007;31(2):77-98. Review.

PMID:
18806312
10.

Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Deaglio S, Robson SC.

Adv Pharmacol. 2011;61:301-32. doi: 10.1016/B978-0-12-385526-8.00010-2. Review.

11.

[Ecto-nucleotidases of ectonucleoside triphosphate diphosphohydrolase family: structure, localization and functional significance].

Iablons'ka SV, Rybal'chenko VK.

Ukr Biokhim Zh (1999). 2010 May-Jun;82(3):5-17. Review. Ukrainian.

PMID:
21328873
12.
13.

Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.

Bai A, Robson S.

Purinergic Signal. 2015 Sep;11(3):317-9. doi: 10.1007/s11302-015-9457-4. Epub 2015 Jun 10. Review.

14.

Immunity at the surface: homeostatic mechanisms of the skin immune system.

Williams IR, Kupper TS.

Life Sci. 1996;58(18):1485-507. Review.

PMID:
8649179
15.

Extracellular ATP and adenosine: The Yin and Yang in immune responses?

Faas MM, Sáez T, de Vos P.

Mol Aspects Med. 2017 Jun;55:9-19. doi: 10.1016/j.mam.2017.01.002. Epub 2017 Jan 16. Review.

PMID:
28093236
16.

CD39: Interface between vascular thrombosis and inflammation.

Kanthi YM, Sutton NR, Pinsky DJ.

Curr Atheroscler Rep. 2014 Jul;16(7):425. doi: 10.1007/s11883-014-0425-1. Review.

PMID:
24838375
17.

CD39 and CD73 in immunity and inflammation.

Antonioli L, Pacher P, Vizi ES, Haskó G.

Trends Mol Med. 2013 Jun;19(6):355-67. doi: 10.1016/j.molmed.2013.03.005. Epub 2013 Apr 17. Review.

18.

Purinergic signaling during intestinal inflammation.

Longhi MS, Moss A, Jiang ZG, Robson SC.

J Mol Med (Berl). 2017 Sep;95(9):915-925. doi: 10.1007/s00109-017-1545-1. Epub 2017 May 26. Review.

PMID:
28547076
19.

CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Kishore BK, Robson SC, Dwyer KM.

Purinergic Signal. 2018 Jan 13. doi: 10.1007/s11302-017-9596-x. [Epub ahead of print] Review.

PMID:
29332180
20.

Targeting stenosis with nucleotide-hydrolyzing enzymes.

Kaczmarek E, Koziak K.

Curr Pharm Biotechnol. 2011 Nov;12(11):1799-804. Review.

PMID:
21902627

Supplemental Content

Support Center